Browse
Submit Data
Databases
API
Help

Dataset Information

12 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Genomics, Transcriptomics, and Minimal Residual Disease Detection: The Winning Team to Guide Treatment of Acute Lymphoblastic Leukemia

ABSTRACT: Summary: Cytogenetics supported by additional molecular analyses and minimal residual disease detection have been successfully combined to improve the outcome of childhood acute lymphoblastic leukemia (ALL). Results from the St. Jude Total Therapy Study 16 demonstrate that some of the recently identified ALL subtypes can further guide risk stratification. See related article by Jeha et al., p. 326.

SUBMITTER: Segers H

PROVIDER: S-EPMC8504769 | biostudies-literature |

REPOSITORIES: biostudies-literature

ACCESS DATA

Json Xml

Similar Datasets

Detection of minimal residual disease in B lymphoblastic leukemia using viSNE.

Project description: Not available

| S-EPMC5981136 | biostudies-literature

New markers for minimal residual disease detection in acute lymphoblastic leukemia.

Project description: Not available

| S-EPMC3122946 | biostudies-literature

Deep-sequencing approach for minimal residual disease detection in acute lymphoblastic leukemia.

Project description: Not available

| S-EPMC3537310 | biostudies-literature

New markers for minimal residual disease detection in acute lymphoblastic leukemia

Project description:To identify new markers for minimal residual disease (MRD) detection in acute lymphoblastic leukemia (ALL), we compared genome-wide gene expression of lymphoblasts from 270 patients with newly diagnosed childhood ALL to that of normal CD19 CD10 B-cell progenitors (n=4). Expression of 30 genes differentially expressed by > 3-fold in at least 25% of cases of ALL (or 40% of ALL subtypes) was tested by flow cytometry in 200 B-lineage ALL and 61 nonleukemic BM samples, including samples containing hematogones. Of the 30 markers, 22 (CD44, BCL2, HSPB1, CD73, CD24, CD123, CD72, CD86, CD200, CD79b, CD164, CD304, CD97, CD102, CD99, CD300a, CD130, PBX1, CTNNA1, ITGB7, CD69, CD49f) were differentially expressed in up to 81.4% of ALL cases; expression of some markers was associated with the presence of genetic abnormalities. Results of MRD detection by flow cytometry with these markers correlated well with those of molecular testing (52 follow-up samples from 18 patients); sequential studies during treatment and diagnosis-relapse comparisons documented their stability. When incorporated in 6-marker combinations, the new markers afforded the detection of 1 leukemic cell among 105 BM cells. These new markers should allow MRD studies in all B-lineage ALL patients, and substantially improve their sensitivity.

2011-04-20 | GSE28497 | GEO

Detection of minimal residual disease in B lymphoblastic leukemia by high-throughput sequencing of IGH.

Project description: Not available

| S-EPMC5142743 | biostudies-literature

Circulating microRNAs as minimal residual disease biomarkers in childhood acute lymphoblastic leukemia.

Project description: Not available

| S-EPMC6854698 | biostudies-literature

Minimal Residual Disease in Acute Lymphoblastic Leukemia: Current Practice and Future Directions.

Project description: Not available

| S-EPMC8069391 | biostudies-literature

Minimal Residual Disease Evaluation in Childhood Acute Lymphoblastic Leukemia: An Economic Analysis.

Project description: Not available